Edition:
United States

People: Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

42.44USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$42.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
66,083
52-wk High
$68.57
52-wk Low
$28.54

Hague, Richard 

Mr. Richard Hague is Chief Commercial Officer of Anika Therapeutics, Inc. From November 2014 through joining our company, Mr. Hague was the Vice President Sales and Marketing at TEI Medical where he was responsible for driving the revenue growth of that corporation’s dermal scaffold product, as well as for the build out of its sales and marketing teams. From 2011 through 2014, Mr. Hague was Vice President Sales, Marketing, and Commercial Operations for Sanofi Biosurgery’s Cell Therapy and Regenerative Medicine group. In this role, Mr. Hague was responsible for the global commercial operations of the group’s products in the orthopedic sports medicine and burn markets. Prior to this, Mr. Hague was the Senior Director and Head of Sales for Genzyme Biosurgery where he headed the U.S. sales team in the orthopedics and sports medicine market. Mr. Hague holds a B.S. in marketing from the University of Connecticut.

Basic Compensation

Total Annual Compensation, USD 428,723
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 626,427
Fiscal Year Total, USD 1,055,150

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Darling

1,782,210

Sylvia Cheung

1,272,690

Thomas Finnerty

--

Edward Ahn

1,090,660

Richard Hague

1,055,150

Joseph Bower

188,959
As Of  30 Dec 2017